Details for: TYSABRI
Company: BIOGEN CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02286386 | TYSABRI | NATALIZUMAB | 300 MG / 15 ML | SOLUTION | INTRAVENOUS |
Summary Reports
Summary Basis of Decision
Summary Safety Review - TYSABRI (natalizumab) - Blood (hematological) Abnormalities in Newborns whose Mothers were treated with Tysabri During Pregnancy
Summary Safety Review - TYSABRI (natalizumab) - Assessing the Potential Risk of Hemolytic Anemia
Summary Safety Review - TYSABRI (natalizumab) - Blood (hematological) Abnormalities in Newborns whose Mothers were treated with Tysabri During Pregnancy
Summary Safety Review - TYSABRI (natalizumab) - Assessing the Potential Risk of Hemolytic Anemia
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.